大博医疗
(002901)
| 流通市值：96.22亿 | | | 总市值：138.08亿 |
| 流通股本：2.89亿 | | | 总股本：4.14亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,529,257,676.1 | 964,129,205.76 | 427,279,900.69 | 1,533,121,281.8 |
| 营业收入 | 1,529,257,676.1 | 964,129,205.76 | 427,279,900.69 | 1,533,121,281.8 |
| 二、营业总成本 | 1,262,754,773.03 | 815,182,154.53 | 368,536,592.16 | 1,459,172,978.12 |
| 营业成本 | 482,102,549.84 | 319,577,758.3 | 136,138,675.23 | 492,239,429.55 |
| 税金及附加 | 18,673,075.15 | 11,492,097.54 | 4,718,941.98 | 14,361,576.58 |
| 销售费用 | 467,317,956 | 301,914,331.11 | 140,935,711.8 | 564,964,583.13 |
| 管理费用 | 90,572,845.99 | 56,274,543.37 | 27,562,023.13 | 125,518,339.26 |
| 研发费用 | 214,640,411.75 | 135,797,967.17 | 59,950,671.27 | 285,275,500.97 |
| 财务费用 | -10,552,065.7 | -9,874,542.96 | -769,431.25 | -23,186,451.37 |
| 其中:利息费用 | 5,520,810.76 | 4,527,475.75 | 2,704,132.51 | 7,158,603.61 |
| 其中:利息收入 | 22,491,625.29 | 15,061,870.19 | 7,799,477.35 | 29,905,982.49 |
| 加:公允价值变动收益 | 1,040,853.13 | -5,039,907.91 | -1,427,782.11 | 5,601,864.97 |
| 加:投资收益 | 11,446,084.53 | 7,926,313.7 | 4,199,276.19 | 9,746,765.11 |
| 资产处置收益 | -278,340.85 | 89,550.57 | 24,936.69 | 302,702.99 |
| 资产减值损失(新) | -28,019,176.85 | -17,922,645.27 | -4,977,238.57 | -50,141,494.2 |
| 信用减值损失(新) | 4,237,821.73 | 3,264,356.95 | 2,966,999.15 | 922,211.89 |
| 其他收益 | 33,673,823.33 | 26,780,737.65 | 17,025,582.71 | 62,855,864.84 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 288,603,968.09 | 164,045,456.92 | 76,555,082.59 | 103,236,219.28 |
| 加:营业外收入 | 397,703.04 | 97,259.45 | 64,099.31 | 218,780.24 |
| 减:营业外支出 | 1,336,132.62 | 1,086,899.28 | 622,800.99 | 3,714,158.51 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 287,665,538.51 | 163,055,817.09 | 75,996,380.91 | 99,740,841.01 |
| 减:所得税费用 | 24,516,201.53 | 12,248,066.64 | 8,794,923.09 | 13,404,821.8 |
| 六、净利润 | 263,149,336.98 | 150,807,750.45 | 67,201,457.82 | 86,336,019.21 |
| 持续经营净利润 | 263,149,336.98 | 150,807,750.45 | 67,201,457.82 | 86,336,019.21 |
| 归属于母公司股东的净利润 | 239,875,968.2 | 138,243,990.01 | 61,728,900.6 | 58,972,461.01 |
| 少数股东损益 | 23,273,368.78 | 12,563,760.44 | 5,472,557.22 | 27,363,558.2 |
| (一)基本每股收益 | 0.58 | 0.33 | 0.15 | 0.14 |
| (二)稀释每股收益 | 0.58 | 0.33 | 0.15 | 0.14 |
| 八、其他综合收益 | -1,244,015.8 | -961,868.75 | -332,290.03 | -196,716.25 |
| 归属于母公司股东的其他综合收益 | -993,192.91 | -909,999.09 | -365,937.91 | -197,884.59 |
| 九、综合收益总额 | 261,905,321.18 | 149,845,881.7 | 66,869,167.79 | 86,139,302.96 |
| 归属于母公司股东的综合收益总额 | 238,882,775.29 | 137,333,990.92 | 61,362,962.69 | 58,774,576.42 |
| 归属于少数股东的综合收益总额 | 23,022,545.89 | 12,511,890.78 | 5,506,205.1 | 27,364,726.54 |
| 公告日期 | 2024-10-31 | 2024-08-29 | 2024-04-30 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |